http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Worksport schedules Q2 2026 earnings call for August 11
-
FDA accepts PolyPid's D-PLEX100 NDA with priority review
-
Ionis Pharmaceuticals chief scientific officer to retire in 2027
-
VERAXA Biotech files first BiTAC patent applications, portfolio tops 50
-
Lightbridge added to Solactive uranium index tracked by Global X ETF
-
Bain Capital leads $1.5B investment in Eaton Fiber for Verizon expansion
-
Core Scientific adds Mark Adams to its board of directors
-
NurExone names David Stolick to board, hires investor firm
-
Rodeo at the Racetrack to hold 3-day event at Sam Houston in 2026
-
Interactive Brokers expands AI account access to MCP-compatible tools
-
Hyundai signs multi-year deal with Inter Miami CF as auto partner
-
Cipla wins FDA approval for generic Advair Diskus in all strengths
-
Auxly Cannabis begins trading after 14:1 share consolidation
-
Core Scientific posts Q2 2026 revenue of $164M, reports AMD partnership
-
AST SpaceMobile schedules August 5 Falcon 9 launch for 3 satellites
-
Denison Mines begins full-scale construction at Phoenix uranium mine
-
HII expands distributed shipbuilding to amphibious transport program
-
PreveCeutical closes third tranche, raising $200,000 in placement
-
Entera Bio prices $275M private placement led by BVF Partners
-
Entera Bio prices $275 million private placement led by BVF Partners
-
Lightbridge and QNI sign non-binding HALEU fuel supply MoU
-
CytomX Therapeutics adds oncologist Charles Fuchs to its board
-
Arrowhead completes enrollment in Phase 3 HoFH drug trial
-
DeFi Technologies CEO cites crypto market decline in shareholder letter
-
VERAXA Biotech advances VXA-222 bispecific ADC program with OmniAb
-
Veraxa Biotech shareholders approve all EGM resolutions with 99.94% vote
-
Merck signs HIV prevention drug licenses covering 129 countries
-
EU panel backs Gilead's Trodelvy plus Keytruda for breast cancer
-
Victory Capital names Nicolas Calcoen to board amid director change
-
Veraxa Biotech names Christoph Erkel as chief scientific officer
-
CN and Union Pacific sign rail network access swap agreement
-
CN and Union Pacific sign agreement tied to Union Pacific-Norfolk Southern merger
-
Motorsport Games adopts stockholder rights plan expiring July 2027
-
Blackbaud adds four AI agents for nonprofit and education sectors
-
Worksport reports 132% gross profit rise from April to June 2026
-
Arrowhead's plozasiran hits Phase 3 endpoints in triglyceride study
-
Auxly Cannabis to consolidate shares 14-to-1 on TSX July 28
-
Greenwich LifeSciences wins UK approval to expand breast cancer trial
-
Gilead and Merck HIV pill shows strong results in Phase 3 trials
-
Ainos reports 613 million scent data points collected since Dec. 2025
-
ReElement Technologies adds 13 employees to scale Indiana refining ops
-
PlayOn Sports names new chief product and financial officers
-
HII appoints Michael DeBernardis as chief counsel of Mission Technologies
-
PolyPid partners with Azurity for D-PLEX100 U.S. and Canada rights
-
Bitdeer bitcoin output rises 388% Y/Y to 990 BTC in June
-
Cunard to refit Queen Victoria in Rotterdam this autumn
-
Scholar Rock says apitegromab EU approval delayed by facility review
-
Monopar adds commercial leaders ahead of potential ALXN1840 launch
-
Veraxa Biotech receives regulatory guidance on BiTAC-TCE cancer therapy
-
Greenwich LifeSciences updates FLAMINGO-01 trial design and reports financials
